Climb Global Solutions (NASDAQ:CLMB) reported quarterly earnings of $1.06 per share. This is a 35.9 percent increase over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $88.91 million which beat the analyst consensus estimate of $84.64 million by 5.04 percent. This is a 17.74 percent increase over sales of $75.51 million the same period last year.
Castle Biosciences Announces Publication Of Study Demonstrating DecisionDx-SCC Test Identifies High-Risk SCC Patients Benefiting Most From ART
In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher metastasis-free survival (MFS) rates, on average, and slowed disease progression compared to Class 2B patients who did not receive ART
